CME
Who Is the Best Candidate for Sequencing Sacituzumab Govitecan Before T-DXd in HR+ Breast Cancer?
July 17, 2023
Host: Sarah Sammons, MD
This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ dis
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!